VictoriaNachar Profile Banner
Victoria Nachar Profile
Victoria Nachar

@VictoriaNachar

Followers
460
Following
3K
Media
42
Statuses
1K

Hematology Clinical Pharmacist @UMRogelCancer 〽️#GoBills #Buffalove

Ann Arbor, MI
Joined June 2011
Don't wanna be here? Send us removal request.
@VictoriaNachar
Victoria Nachar
5 years
✨ DREAMS DO COME TRUE ✨ Thank you @ratemyskyperoom
@ratemyskyperoom
Room Rater
5 years
Lovely art. Nice shelves. Well curated/presented. Pineapple for the win. 10/10 @VictoriaNachar
3
6
186
@RahulBanerjeeMD
Rahul Banerjee, MD, FACP
14 days
10/ #ASH25 Abstract 720: 1st-line CRS Tx with dex in #MMsm bsAbs (McElwee @thisisJamesD et al) "Pocket dex": equal efficacy, way cheaper / simpler than toci, albeit >1 dose more likely. This makes outpt bsAb SUD *way* easier for pts. As I now say: #Downwithdex #ExceptforCRS !
2
3
11
@WolverHeme
WolverHeme
1 month
Check out our latest episode, "Chill for 5: The Febrile Neutropenia Survival Guide"! Plus find out why @ajperissinotti was laughing at @Berninini for wearing this ridiculous tuque ❄️#wolverheme #leusm https://t.co/2FPsr5qbqC
2
5
12
@WolverHeme
WolverHeme
2 months
We're BACK after a summer break! Listen to our latest episode "Prophy and Pints"! Let us de-mystify antimicrobial prophylaxis and help you choose the best regimen for your patients! 🦠💊 @Berninini @ajperissinotti
Tweet card summary image
open.spotify.com
WolverHeme Happy Hour · Episode
1
4
12
@BloodCancerJnl
Blood Cancer Journal
4 months
Dexamethasone for the management of CRS Related to teclistamab in patients with relapsed/refractory multiple myeloma | Blood Cancer Journal
Tweet card summary image
nature.com
Blood Cancer Journal - Dexamethasone for the management of CRS Related to teclistamab in patients with relapsed/refractory multiple myeloma
1
8
34
@VictoriaNachar
Victoria Nachar
6 months
Me, in my car. Well done @WolverHeme
@WolverHeme
WolverHeme
6 months
🔔We had to convene an emergency meeting with @dgermain21 and @ManniMD1 just for this episode ‼️ "ODAC - Our Decisions Are Confusing" @ajperissinotti @Berninini https://t.co/TiIEIIff5p
0
2
5
@MedscapePharm
Medscape Pharmacists
8 months
📘 Dive into BCMA-directed therapies for MM and strengthen your treatment approach with new data! 📍 Oregon Convention Center, 777 NE Martin Luther King Jr Blvd, Room B113-114 📢 Learn more: https://t.co/dKGQkKHRoR Join 👉 @KirollosPharmD @VictoriaNachar @jayinabox #HOPA2025
0
2
2
@thisisJamesD
James Davis, PharmD, BCOP
9 months
🌶️Hot off the press! 🌶️ Dexamethasone for CRS with teclistamab. You don't need toci for grade 1 CRS! great team work - @VictoriaNachar @CWagnerPharmD @kczmj @KLratermann @MikhailaPharmD @KG_PharmD @khouri_jack https://t.co/lxpTdhkQie
3
26
110
@HOPArx
HOPARX
10 months
HOPA's OCC, with the participation of @ASCO Quality Training Programs, has developed practice-based tools to aid in developing and improving initiatives and the care of patients receiving oral anticancer agents (OAAs). Read the full article @JCO_ASCO: https://t.co/1PNjB3D4dx
1
3
7
@thisisJamesD
James Davis, PharmD, BCOP
1 year
How do you treat low grade CRS due to myeloma bispecifics? We investigated differences of using dexamethasone and toci in CRS with teclistamab in six US centers and found as few as one 10mg dex dose is enough to alleviate low grade CRS. #ASH24 @VictoriaNachar @kczmj @j_snyder0132
3
11
54
@WolverHeme
WolverHeme
1 year
Time for a MANTLE CELL MASTERCLASS with @LymphClinician @ajperissinotti and @Berninini ! Should TRIANGLE change the SOC? Where do bispecifics and CAR-T fit into the treatment paradigm? Listen and find out! #lymsm #twitterx
Tweet card summary image
creators.spotify.com
In this episode, Tycel Phillips, MD joins Anthony and Bernie to discuss updates in Mantle Cell Lymphoma, including the TRIANGLE study and the recently published results of glofitamab in R/R MCL....
3
13
63
@kczmj
Zahra M, PharmD, MBA, BCOP, FHOPA
1 year
Bispecific antibodies are changing treatment in Hem/Onc.. but adoption has been mixed due to logistics! Out now in @JADPRO, we aim to tackle some FAQ! 🙏🏻 to @amirsali101 @thisisJamesD @SandahlTyler @VictoriaNachar @KPsiBCOP! #oncopharm #TwitterRx
Tweet card summary image
jadpro.com
Bispecific antibodies (BsAbs) have emerged as crucial therapeutic agents; however, multidisciplinary collaboration is essential to ensure optimal patient outcomes amid operational complexities. Read...
2
12
47
@VictoriaNachar
Victoria Nachar
2 years
Join us!
@ProCEhealth
ProCE
2 years
We’re 1 week away from our virtual webinar on the evolving landscape of #myelofibrosiscare. Leading pharmacists @VictoriaNachar, @JustinArnall1 will discuss: ✅ Key considerations for managed care professionals ✅ Varied roles of pharmacists Register: https://t.co/bPqoYKTsGZ
0
4
7
@WolverHeme
WolverHeme
2 years
Check out our latest episode "Myeloma Madness with the Myeloma Man", where @ajperissinotti and @Berninini discuss the recent FDA approval updates on CAR-T in myeloma with our good friend and myeloma expert @ManniMD1
Tweet card summary image
creators.spotify.com
In this episode, Anthony and Bernie are joined by Multiple Myeloma expert Dr. Manni Mohyuddin, to discuss the recent FDA approval updates of CAR-T in this disease state. We also discuss the hotly...
3
15
54
@ProCEhealth
ProCE
2 years
Managed care professionals looking to stay updated on the latest in #myelofibrosiscare. Join our CPE-certified webinar with @VictoriaNachar, @JustinArnall1. Learn about treatment advances & pharmacist roles in patient care. 👉 Add it to your calendar: https://t.co/bPqoYKSURr
0
1
1
@VictoriaNachar
Victoria Nachar
2 years
Dual target dilemma lead by the incredible @thisisJamesD
@thisisJamesD
James Davis, PharmD, BCOP
2 years
#epcoritamab vs #glofitamab battle of the bispecifics. hopefully the first of many collabs with @VictoriaNachar 👏🤓😎 #lymsm #oncopharm
2
2
20
@VictoriaNachar
Victoria Nachar
2 years
The Taylor swift references - incredible. Literally 10/10. Chefs kiss. 🤌@ajperissinotti @Berninini @maddyochs @JustinArnall1
@WolverHeme
WolverHeme
2 years
Newest episode is out! Join #teambadblood🩸as we go our own Eras Tour of Hemophilia treatment! @JustinArnall1 @maddyochs @Berninini @ajperissinotti #classicalhematology #itsnotbenign
0
2
10
@VictoriaNachar
Victoria Nachar
3 years
What’s cooler than being cool? Being Maddy Ochs that’s what! Great talk on cold agglutinin disease by the rockstar @maddyochs #HOPAAC23
1
1
20